Health Technology · Pharmaceuticals: Major · NSE: ACUTAAS · data 2026-10-09

Acutaas Chemicals Ltd

Health check: Strong (7.5/10 on quality, valuation vs sector, growth and momentum).

Open full analysis — chart, results, balance sheet, red flags →

Key figures

Price

₹3,160.6

Market cap

₹25,038 cr

P/E

67.2

P/B

—

ROE

24.0%

ROCE

28.9%

Debt / equity

0.02

Dividend yield

0.08%

1-year return

125.1%

52-week high

₹3,740

52-week low

₹1,467.5

Operating margin

34.5%

Growth

Revenue (last 12 months)	₹1,462 cr
Net profit (last 12 months)	₹386 cr
Sales growth, 3 years (yearly)	29.5%
Profit growth, 3 years (yearly)	62.3%

Similar companies

Wockhardt Limited (WOCKPHARMA) · Neuland Laboratories Ltd. (NEULANDLAB) · Piramal Pharma Limited (PPLPHARMA) · Shilpa Medicare Limited (SHILPAMED) · Caplin Point Laboratories Limited (CAPLIPOINT)

The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.

Open ACUTAAS in NSE Scanner →